Diabetes

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

ADA 2021: The investigational exendin-4-based GLP-1 RA was associated with a 27% decrease in risk for a CV event and a 32% reduction in risk for CKD progression.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not GLP-1 receptor agonists were on board at study baseline.

The much anticipated results from the SURPASS 2 clinical trial demonstrated reductions in A1c and body weight with tirzepatide that were significant and superior to those with semaglutide.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.

STEP program investigator Robert F. Kushner, MD, reviews the "unprecedented" clinical trial results for semaglutide 2.4 mg and speaks specifically to primary care clinicians treating obesity.

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.

The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.

The novel Bigfoot Unity Diabetes Management System could help improve insulin dosing in patients with type 1 or type 2 diabetes.

Adults in their 30s and 40s who had high BMI in adolescence were at highest risk for type 2 diabetes and early MI, regardless of adult BMI, after 24 years of follow-up, a new study finds.

The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.

MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.

MOBILE study lead author Thomas W. Martens, MD, discusses results of the study which was designed to capture CGM results in real-world primary care practice.

Patients with T2D see significant improvement in glycemic control using continuous glucose monitoring. MOBILE study lead author Thomas W. Martens, MD, highlights the evidence.

Assessment of prediabetes subphenotypes is a novel approach to better screening, prevention, and treatment for patients at risk of progression to T2D. Find out how much you know about it.

A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.

Analysis of NHANES data shows significant downturns in control of the 3 risk factors in patients with diabetes, which could mean population-level increases in related illness.

New research proposes pathophysiology-based subphenotyping of individuals at increased risk for T2D; 6 are suggested to help refine screening, prevention, and treatment.

An Australian study of more than 7000 adults suggests 2 servings of whole fruit per day helps preserve insulin sensitivity and mitigate risk for type 2 diabetes.

Semaglutide 2.4 mg is the first drug approved for chronic weight management since 2014 and the first once-weekly GLP-1 receptor agonist to be approved for that purpose.

MOBILE study group: in patients with type 2 diabetes on a less intensive insulin regimen, CGM use lowered A1c and increased time in target glucose range vs traditional blood glucose monitoring.

A new study reveals that nearly three-quarters of medication organizer packages contain a drug class from which a single pill could be lethal for a child.

In people without diabetes and considered low risk for CVD, A1c was associated in a graded, positive fashion with subclinical atherosclerosis, even at prediabetes levels.

SGLT-2 inhibitor investigator Mikhail Kosiborod, MD, answers questions about patient selection for the class of drugs, now with approval to treat much more than type 2 diabetes.

The landmark Diabetes Prevention Program (DPP) trial and follow-up studies proved that risk of T2D can be reduced in patients at high risk for the disease. Do you know by how much?

CKD IQ Test Preview: When should you suspect kidney disease? What measure is used to define chronic kidney disease? What UACR test result indicates albuminuria? Good luck.